Abstract
A 48-year-old man was administered bevacizumab+FOLFOX for lymph node recurrence of colon cancer in the abdominal cavity, and developed serious thrombosis of the portal system after 6 courses of the chemotherapy. We discontinued it promptly and anticoagulant therapy with urokinase was started immediately, but a complete dissolution was not achieved. Preservation therapy using anticoagulants for a long duration was effective for controling the of clinical symptom of thrombosis. The result of 6 courses of chemotherapy was CR, and the effect continues today, without further treatment 2 years later.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bevacizumab
-
Colonic Neoplasms / drug therapy*
-
Colonic Neoplasms / pathology
-
Fibrinolytic Agents / therapeutic use*
-
Fluorouracil / administration & dosage
-
Fluorouracil / adverse effects
-
Humans
-
Leucovorin / administration & dosage
-
Leucovorin / adverse effects
-
Male
-
Mesenteric Veins / pathology*
-
Middle Aged
-
Neoplasm Staging
-
Organoplatinum Compounds / administration & dosage
-
Organoplatinum Compounds / adverse effects
-
Recurrence
-
Urokinase-Type Plasminogen Activator / therapeutic use*
-
Venous Thrombosis / chemically induced
-
Venous Thrombosis / drug therapy*
Substances
-
Antibodies, Monoclonal, Humanized
-
Fibrinolytic Agents
-
Organoplatinum Compounds
-
Bevacizumab
-
Urokinase-Type Plasminogen Activator
-
Leucovorin
-
Fluorouracil